Opinion|Videos|October 2, 2024
Navigating Toxicity: Comparing Third-Line mCRC Therapies
Medical experts compare the toxicity profiles of FTD/TPI plus bevacizumab, regorafenib, and fruquintinib, and discuss practical strategies for managing treatment-related toxicities with these third-line therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do the toxicity profiles differ with FTD/TPI plus bevacizumab, as compared with regorafenib or fruquintinib, and how might these different toxicity profiles be leveraged when making treatment selections?
- What are some key, practical strategies you use to manage treatment-related toxicities with these third-line therapies?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care
2
Trump Childhood Vaccine Order: What It Means for Parents and Payers
3
CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD
4
OCTOPUS Trial Aims to Speed Access to Rare Sarcoma Drugs
5